DURECT Corporation (NASDAQ:DRRX) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.02, Bloomberg Earnings reports. DURECT Corporation had a negative net margin of 232.05% and a negative return on equity of 318.49%.

Shares of DURECT Corporation (NASDAQ:DRRX) traded up 4.17% during midday trading on Tuesday, hitting $1.75. The company had a trading volume of 1,189,320 shares. The company’s market capitalization is $248.44 million. DURECT Corporation has a 52 week low of $0.74 and a 52 week high of $1.95. The firm’s 50 day moving average is $1.65 and its 200 day moving average is $1.20.

DRRX has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of DURECT Corporation in a research report on Sunday, June 25th. Stifel Nicolaus upgraded DURECT Corporation from a “hold” rating to a “buy” rating and upped their price target for the company from $1.25 to $3.00 in a research report on Wednesday, July 12th.

COPYRIGHT VIOLATION WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/08/durect-corporation-nasdaqdrrx-issues-quarterly-earnings-results.html.

Several hedge funds have recently bought and sold shares of DRRX. State Street Corp boosted its stake in DURECT Corporation by 2.5% in the fourth quarter. State Street Corp now owns 1,919,694 shares of the specialty pharmaceutical company’s stock valued at $2,570,000 after buying an additional 46,450 shares during the last quarter. Teachers Advisors LLC boosted its stake in DURECT Corporation by 16.0% in the fourth quarter. Teachers Advisors LLC now owns 224,361 shares of the specialty pharmaceutical company’s stock valued at $301,000 after buying an additional 31,001 shares during the last quarter. Wells Fargo & Company MN boosted its stake in DURECT Corporation by 152.3% in the first quarter. Wells Fargo & Company MN now owns 381,802 shares of the specialty pharmaceutical company’s stock valued at $400,000 after buying an additional 230,500 shares during the last quarter. Tocqueville Asset Management L.P. boosted its stake in DURECT Corporation by 59.8% in the first quarter. Tocqueville Asset Management L.P. now owns 808,500 shares of the specialty pharmaceutical company’s stock valued at $849,000 after buying an additional 302,500 shares during the last quarter. Finally, Ingalls & Snyder LLC boosted its stake in DURECT Corporation by 1.3% in the first quarter. Ingalls & Snyder LLC now owns 2,050,082 shares of the specialty pharmaceutical company’s stock valued at $2,153,000 after buying an additional 26,000 shares during the last quarter. 52.72% of the stock is currently owned by institutional investors.

About DURECT Corporation

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Earnings History for DURECT Corporation (NASDAQ:DRRX)

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.